ES2214866T3 - Fenilacetilglutamina, fenilacetilisoglutamina y/o fenilacetato para el tratamiento de enfermedades neoplasicas. - Google Patents

Fenilacetilglutamina, fenilacetilisoglutamina y/o fenilacetato para el tratamiento de enfermedades neoplasicas.

Info

Publication number
ES2214866T3
ES2214866T3 ES99932179T ES99932179T ES2214866T3 ES 2214866 T3 ES2214866 T3 ES 2214866T3 ES 99932179 T ES99932179 T ES 99932179T ES 99932179 T ES99932179 T ES 99932179T ES 2214866 T3 ES2214866 T3 ES 2214866T3
Authority
ES
Spain
Prior art keywords
formula
compound
carbon atoms
day
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99932179T
Other languages
English (en)
Spanish (es)
Inventor
Stanislaw R. Burzynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2214866T3 publication Critical patent/ES2214866T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
ES99932179T 1998-07-23 1999-07-02 Fenilacetilglutamina, fenilacetilisoglutamina y/o fenilacetato para el tratamiento de enfermedades neoplasicas. Expired - Lifetime ES2214866T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US121567 1987-11-17
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (1)

Publication Number Publication Date
ES2214866T3 true ES2214866T3 (es) 2004-09-16

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99932179T Expired - Lifetime ES2214866T3 (es) 1998-07-23 1999-07-02 Fenilacetilglutamina, fenilacetilisoglutamina y/o fenilacetato para el tratamiento de enfermedades neoplasicas.

Country Status (20)

Country Link
US (2) US6258849B1 (2)
EP (1) EP1098643B1 (2)
JP (2) JP2002521329A (2)
KR (4) KR100399658B1 (2)
CN (3) CN100400039C (2)
AT (1) ATE257378T1 (2)
AU (1) AU759278B2 (2)
BR (1) BR9912356A (2)
CA (1) CA2336945C (2)
DE (1) DE69914084T2 (2)
DK (1) DK1098643T3 (2)
EA (1) EA004179B1 (2)
ES (1) ES2214866T3 (2)
ID (1) ID28160A (2)
IL (1) IL140848A (2)
NZ (1) NZ509244A (2)
PL (1) PL213698B1 (2)
PT (1) PT1098643E (2)
WO (1) WO2000004894A2 (2)
ZA (1) ZA200100622B (2)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
DK1313697T3 (da) 2000-08-29 2006-04-10 Nobex Corp Immunregulatoriske forbindelser, derivater deraf samt anvendelse deraf
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
US20060058383A1 (en) * 2004-07-28 2006-03-16 Peng Huang Propyl 3-bromo-2-oxopropionate and derivatives as novel anticancer agents
SI2153870T1 (sl) * 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
WO2017031131A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
JP6861708B2 (ja) * 2015-12-30 2021-04-21 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 除脂肪体重を測定するための方法
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
AU2018282735A1 (en) * 2017-06-12 2020-02-06 Stanislaw R. Burzynski Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
EP4731793A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating pancreatic cancer
EP4731792A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ATE310505T1 (de) 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
CN1660061A (zh) 2005-08-31
EP1098643B1 (en) 2004-01-07
KR100417101B1 (ko) 2004-02-05
DE69914084D1 (de) 2004-02-12
WO2000004894A3 (en) 2000-04-27
US6943192B2 (en) 2005-09-13
KR20030027088A (ko) 2003-04-03
CN1605334A (zh) 2005-04-13
CA2336945A1 (en) 2000-02-03
JP2002521329A (ja) 2002-07-16
IL140848A0 (en) 2002-02-10
ZA200100622B (en) 2002-06-26
AU4854299A (en) 2000-02-14
PT1098643E (pt) 2004-05-31
AU759278B2 (en) 2003-04-10
NZ509244A (en) 2004-02-27
EP1098643A2 (en) 2001-05-16
EA200100168A1 (ru) 2001-08-27
KR20030027087A (ko) 2003-04-03
DE69914084T2 (de) 2004-10-28
KR100414587B1 (ko) 2004-01-13
JP2011051993A (ja) 2011-03-17
DK1098643T3 (da) 2004-05-24
WO2000004894A2 (en) 2000-02-03
HK1037142A1 (en) 2002-02-01
CN1191064C (zh) 2005-03-02
PL213698B1 (pl) 2013-04-30
US20010044466A1 (en) 2001-11-22
BR9912356A (pt) 2001-04-17
KR100417100B1 (ko) 2004-02-05
ATE257378T1 (de) 2004-01-15
IL140848A (en) 2005-05-17
ID28160A (id) 2001-05-10
PL345959A1 (en) 2002-01-14
CA2336945C (en) 2008-11-18
CN1319010A (zh) 2001-10-24
CN100400039C (zh) 2008-07-09
US6258849B1 (en) 2001-07-10
EA004179B1 (ru) 2004-02-26
KR20030027089A (ko) 2003-04-03

Similar Documents

Publication Publication Date Title
ES2214866T3 (es) Fenilacetilglutamina, fenilacetilisoglutamina y/o fenilacetato para el tratamiento de enfermedades neoplasicas.
EP1066830B1 (en) Uses and compositions for treating primary and secondary tumors of the central nervous system (cns)
ES2425083T3 (es) Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
ES2616315T3 (es) Profármacos de ibuprofeno solubles en agua cargados positivamente con una velocidad de penetración en la piel muy rápida
ES2704848T3 (es) Agente de tratamiento y/o agente profiláctico para efectos secundarios de fármacos de cáncer
EP4045058A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
ES2280505T3 (es) Composicion farmaceutica que comprende gamma-butirobetaina.
ES2393398T3 (es) Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer
HK1037142B (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
US4918193A (en) Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
MXPA99000255A (en) Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate
RU2220730C2 (ru) Способ лечения герпетического стоматита
JP4846151B2 (ja) 骨髄もしくは血液幹細胞の移植前の患者のコンディショニングのためのトレオスルファンの使用
RU2022100706A (ru) Способ лечения инсульта с применением трициклического производного
RU2003121205A (ru) Способ профилактики и (или) лечения анемии у детей (варианты)